The Week Ahead: Are Investors Really Too Optimistic About Travere Therapeutics Inc (NASDAQ: TVTX)

Travere Therapeutics Inc (NASDAQ:TVTX) currently has a daily average trading volume of 1.17M but it saw 1209160 shares traded in last market. With a market cap of 726.28M USD, the company’s current market price of $9.54 came rising about 0.42 while comparing to the previous closing price of $9.50. In past 52 weeks, the stock remained buoying in the range of price level as high as $17.57 and as low as $5.12.

Taking a look at 20-day trading activity of Travere Therapeutics Inc (TVTX) gives us an average price of $9.55, while its current price level is -45.70% below from 52-week high level whereas it is 86.33% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.20 while that of 200 days or SMA-200 reads an average of $7.68. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.93% during that period while stretching the period over a month that decreases to 6.04%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 56.37 which implies that the stock is in neutral territory.

Citigroup upgraded its recommendation for the stock as a “Buy” from “Neutral” on December 05, 2023 while assigning a price target range of $7-$10. Citigroup issued its recommendations for the stock as it initiated the price target for the stock is $7.

Over the week, TVTX’s stock price is moving -1.24% down while it is 15.22% when we observe its performance for the past one month. Year-to-date it is 6.12% up and over the past year, the stock is showing a downside performance of -44.50%.

Currently, Travere Therapeutics Inc’s total number of outstanding shares is 76.13M. Company’s return on investment (ROI) stands at -81.84% and return on equity (ROE) at -303.50%. Stock’s beta reads 0.76. Stock has a price to book (P/B) ratio of 9.80 while price to sale or P/S ratio amounts to 3.96. Its return on asset (ROA) is -54.28% on average.